Original artical Prediction of recurrence risk in early breast cancer using human epidermal growth factor 2 and cyclin A2

Chinese Medical Journal

Volumn 123, Issue 4, 2010, Pages 431-437

  Li, Hui Ping ^a   Ji, Jia Fu ^b   Hou, Kuan Yong ^a   Lei, Yu Tao ^a   Zhao, Hong Mei ^a   Wang, Jing ^a   Zheng, Jie ^a   Liu, Jian Ying ^a   Wang, Mo Pei ^a   Xiao, Yu ^a   Wang, You Fan ^a   Lü, You Yong ^b   Sun, Yan ^c  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Breast neoplasms; Cyclin A2; Human epidermal growth factor 2; Prognosis

Indexed keywords

CYCLIN A2; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; HER2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE RISK; UPREGULATION; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLIN A2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77149179760     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.04.009     Document Type: Article

References (25)

1. Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, et al. HER2 and topoisomerase II alpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J 2008; 121: 1965-1968.
2. Zhou B, Yang DQ, Xie F. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Chin Med J 2008; 121: 387-391.
3. Liu Q, Li JG, Zheng XY, Jin F, Dong HT. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin Med J 2009; 122: 2763-2769.
4. Liu XH, Zheng XF, Wang YL. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Chin Med J 2009; 122: 1681-1685.
5. Wang XY, Tan JX, Vasse M, Delpech B, Ren GS. Comparison of hyaluronidase expression, invasiveness and tubule formation promotion in ER (-) and ER (+) breast cancer cell lines in vitro. Chin Med J 2009; 122: 1300-1304.
6. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs. resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol 2008; 21: 363-368.
7. Press MF, Lenq HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007; 67: 2045-2075.
8. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009; 119: 252-266.
9. Yin F, Giuliano AE, Law RE, Van Herle AJ. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 2001; 21: 413-420.
10. Ba Y, Li H, Zhao H, Wang J, Hou K. Analyses on the differentially expressed genes associated with murine double minute2/p53 pathway in breast cancer. Oncol Progress 2008; 6: 7-13.
11. Husdal A, Bukholm G, Bukholm IR. The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cellular Oncol 2006; 28: 107-116.
12. Kühling H, Alm P, Olsson H, Fernö M, Baldetorp B, Parwaresch R, et al. Expression of cyclin E, A and B and prognosis in lymph node-negative breast cancer. J Clin Pathol 2003; 199: 424-431.
13. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol 2005; 58: 509-514.
14. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of Hercep Test in determining HER-2/nue status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-1987.
15. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, et al. Performance comparison of one-color and two-color platforms within the Microarray Quality Control (MAQC) project. Nat Biotechnol 2006; 24: 1140-1150.
16. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006; 24: 3756-3762.
17. Rodriguez-Pinilla M, Rodriguez-Peralto JL, Sanchez JJ, Ballestin C, Diez A, Sanchez-Verde L, et al. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res 2004; 10: 8486-8492.
18. Poikonen P, Sjöström J, Amini R-M, Villman K, Ahlgren J, Blomqvist C. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer 2005; 93: 515-519.
19. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer What are the optimal cutoff values? Histopathology 2007; 51: 491-498.
20. Aaltonen K, Ahlin C, Amini RM, Salonen L, Fjällskog ML, Heikkilä P, et al. Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer 2006; 94: 1697-1702.
21. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008; 26: 5697-5704.
22. Gasparini G, Gullick WJ, Maluta S, Dalla Palma P, Caffo O, Leonardi E, et al. C-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma - an immunocytochemical study. Eur J Cancer 1994; 30A: 16-22.
23. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 2001; 7: 171-177.
24. Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-2436.
25. Tan PH, Lota AS. Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Expert Opin Pharmacother 2008; 9: 2639-2660